tiprankstipranks
Exagen (XGN)
NASDAQ:XGN
US Market
XGN
Exagen
RESEARCH TOOLSreports
Want to see XGN full AI Analyst Report?

Exagen (XGN) Stock Forecast & Price Target

222 Followers
See the Price Targets and Ratings of:

XGN Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Exagen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

XGN Stock 12 Month Forecast

Average Price Target

$8.67
▲(181.39% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Exagen in the last 3 months. The average price target is $8.67 with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 181.39% change from the last price of $3.08.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","7":"$7","12":"$12","4.5":"$4.5","9.5":"$9.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.666666666666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4.5,7,9.5,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,3.5938461538461537,4.127692307692308,4.661538461538462,5.195384615384615,5.729230769230769,6.263076923076923,6.796923076923077,7.330769230769231,7.8646153846153855,8.39846153846154,8.932307692307692,9.466153846153846,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,3.4912820512820515,3.9225641025641025,4.3538461538461535,4.7851282051282045,5.216410256410256,5.647692307692307,6.078974358974358,6.51025641025641,6.94153846153846,7.372820512820512,7.804102564102564,8.235384615384614,{"y":8.666666666666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,3.44,3.82,4.2,4.58,4.96,5.34,5.72,6.1,6.4799999999999995,6.859999999999999,7.24,7.619999999999999,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.14,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.83,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.01,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$10.00Average Price Target$8.67Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on XGN
Andrew Brackmann
William Blair
William Blair
―
Buy
―
Reiterated
05/12/26
Exagen Wins Buy Rating on Strong Q1 Beat, Improving Fundamentals and Clear Path to EBITDA Breakeven
BTIG Analyst forecast on XGN
Mark Massaro
BTIG
BTIG
$9→$8
Buy
159.74%
Upside
Reiterated
05/12/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on XGN
Daniel Brennan
TD Cowen
TD Cowen
$10→$8
Buy
159.74%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Exagen (NASDAQ: XGN) and Liquidia Technologies (NASDAQ: LQDA)
Canaccord Genuity Analyst forecast on XGN
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$8
Buy
159.74%
Upside
Reiterated
05/11/26
Exagen: Buy Rating Reiterated as Strong Execution and Growth Outlook Support Unchanged $8 Price Target
Craig-Hallum Analyst forecast on XGN
William Bonello
Craig-Hallum
Craig-Hallum
$12→$10
Buy
224.68%
Upside
Assigned
03/11/26
Exagen price target lowered to $10 from $12 at Craig-HallumExagen price target lowered to $10 from $12 at Craig-Hallum
KeyBanc Analyst forecast on XGN
Paul Knight
KeyBanc
KeyBanc
$15→$10
Buy
224.68%
Upside
Reiterated
03/11/26
Exagen price target lowered to $10 from $15 at KeyBancExagen price target lowered to $10 from $15 at KeyBanc
B. Riley Securities Analyst forecast on XGN
Anderson Schock
B. Riley Securities
B. Riley Securities
$8
Buy
159.74%
Upside
Reiterated
03/11/26
B. Riley Securities Keeps Their Buy Rating on Exagen (XGN)
Cantor Fitzgerald Analyst forecast on XGN
Ross Osborn
Cantor Fitzgerald
Cantor Fitzgerald
$7→$10
Buy
224.68%
Upside
Reiterated
07/29/25
Exagen price target raised to $10 from $7 at Cantor FitzgeraldExagen price target raised to $10 from $7 at Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on XGN
Andrew Brackmann
William Blair
William Blair
―
Buy
―
Reiterated
05/12/26
Exagen Wins Buy Rating on Strong Q1 Beat, Improving Fundamentals and Clear Path to EBITDA Breakeven
BTIG Analyst forecast on XGN
Mark Massaro
BTIG
BTIG
$9→$8
Buy
159.74%
Upside
Reiterated
05/12/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on XGN
Daniel Brennan
TD Cowen
TD Cowen
$10→$8
Buy
159.74%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Exagen (NASDAQ: XGN) and Liquidia Technologies (NASDAQ: LQDA)
Canaccord Genuity Analyst forecast on XGN
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$8
Buy
159.74%
Upside
Reiterated
05/11/26
Exagen: Buy Rating Reiterated as Strong Execution and Growth Outlook Support Unchanged $8 Price Target
Craig-Hallum Analyst forecast on XGN
William Bonello
Craig-Hallum
Craig-Hallum
$12→$10
Buy
224.68%
Upside
Assigned
03/11/26
Exagen price target lowered to $10 from $12 at Craig-HallumExagen price target lowered to $10 from $12 at Craig-Hallum
KeyBanc Analyst forecast on XGN
Paul Knight
KeyBanc
KeyBanc
$15→$10
Buy
224.68%
Upside
Reiterated
03/11/26
Exagen price target lowered to $10 from $15 at KeyBancExagen price target lowered to $10 from $15 at KeyBanc
B. Riley Securities Analyst forecast on XGN
Anderson Schock
B. Riley Securities
B. Riley Securities
$8
Buy
159.74%
Upside
Reiterated
03/11/26
B. Riley Securities Keeps Their Buy Rating on Exagen (XGN)
Cantor Fitzgerald Analyst forecast on XGN
Ross Osborn
Cantor Fitzgerald
Cantor Fitzgerald
$7→$10
Buy
224.68%
Upside
Reiterated
07/29/25
Exagen price target raised to $10 from $7 at Cantor FitzgeraldExagen price target raised to $10 from $7 at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exagen

3 Months
Kyle Mikson CFACanaccord Genuity
Success Rate
15/22 ratings generated profit
68%
Average Return
+12.44%
Copying Kyle Mikson CFA's trades and holding each position for 3 Months would result in 68.18% of your transactions generating a profit, with an average return of +12.44% per trade.
1 Year
Daniel BrennanTD Cowen
Success Rate
7/12 ratings generated profit
58%
Average Return
+71.29%
Copying Daniel Brennan's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +71.29% per trade.
2 Years
Mark MassaroBTIG
Success Rate
12/20 ratings generated profit
60%
Average Return
+54.20%
Copying Mark Massaro's trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +54.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XGN Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
9
7
12
10
11
Buy
3
1
2
1
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
8
14
11
13
In the current month, XGN has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. XGN average Analyst price target in the past 3 months is 8.67.
Each month's total comprises the sum of three months' worth of ratings.

XGN Financial Forecast

XGN Earnings Forecast

Next quarter’s earnings estimate for XGN is -$0.19 with a range of -$0.21 to -$0.15. The previous quarter’s EPS was -$0.17. XGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year XGN has Performed in-line its overall industry.
Next quarter’s earnings estimate for XGN is -$0.19 with a range of -$0.21 to -$0.15. The previous quarter’s EPS was -$0.17. XGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year XGN has Performed in-line its overall industry.

XGN Sales Forecast

Next quarter’s sales forecast for XGN is $17.79M with a range of $17.00M to $18.30M. The previous quarter’s sales results were $17.31M. XGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year XGN has Performed in-line its overall industry.
Next quarter’s sales forecast for XGN is $17.79M with a range of $17.00M to $18.30M. The previous quarter’s sales results were $17.31M. XGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year XGN has Performed in-line its overall industry.

XGN Stock Forecast FAQ

What is XGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Exagen’s 12-month average price target is 8.67.
    What is XGN’s upside potential, based on the analysts’ average price target?
    Exagen has 181.39% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is XGN a Buy, Sell or Hold?
          Exagen has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Exagen’s price target?
            The average price target for Exagen is 8.67. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $10.00 ,the lowest forecast is $8.00. The average price target represents 181.39% Increase from the current price of $3.08.
              What do analysts say about Exagen?
              Exagen’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of XGN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.